Emzor Pharmaceutical Industries Limited is a wholly private indigenous pharmaceutical manufacturing group founded in 1984 by Dr. Stella C. Okoli, OON. The company is into the manufacture of high quality pharmaceutical products and medical consumables. Today, Emzor has become a household name in Nigeria and a leader in the pharmaceutical market that is known ...
Read more about this company
Develop robust formulations and processes for various dosage forms as required by the company.
Plan and contribute to project-related technical activities.
Review and approve technical documents including Product Development Report, and other relevant documents for regulatory filing purpose.
Interaction with procurement team, API and excipients manufacturers, Machine manufacturers, CROs and CMOs as needed.
Work proactively with other cross-functional groups to execute product/ process improvement and optimization, Product Lifecycle management, change controls associated with Manufacturing and Packaging master records, SOPs and protocols.
Create and review SOPs, as well as review appropriate system documentation and test results for accuracy and completeness and compliance with SOPs/GMP requirement.
Provide relevant documents to Regulatory Affairs in a timely manner for registration filings and Supplements filing.
Review of batch records, process characterization reports, Annual Product Quality Review Report, validation reports and investigation reports where necessary.
Participate in designing and approval of tablet punches and blister change parts.
Review Formulation Development Protocol, Processes and Report to ensure the Development of robust formulations and processes.
Plan and contribute to project-related technical activities by reviewing the activities where required.
Review of technical document and communications shared by procurement team, API and excipients manufacturers, Machine manufacturers, CROs and CMOs as needed.
Review of SOPs, appropriate system documentation and test results for accuracy and completeness and compliance with SOPs/GMP requirement.
Preparation and review of Product Dossier.
Review of batch records, process characterization reports, Annual Product Quality Review Report, validation reports and investigation reports where necessary.
Ensure Pharmaceutical Development Protocol preparation, execution and reporting.
Ensure document preparation i.e., SOPs, Protocols, Master Formula Records.
Review and/ or Approval of prepared document.
Review and/ or Approval of technical drawing (tools and change part), where needed.
Any additional task assigned by Management.
SKILLS REQUIRED:
Minimum of 5-8years of relevant experience in Pharmaceutical Development
Knowledge of Quality by Design (QbD) principles towards dosage form development, planning of trials by DOE for development and execution of trial batches.
Knowledge of current Good Manufacturing Practices.
Member of relevant professional body.
QUALIFICATION:
Minimum of B.Sc., HND or equivalent in Chemistry, Biochemistry, Biological Sciences
AI's Impact on Jobs and Organisations (Nigeria report)This report examines the extent to which AI is affecting jobs and organisations in Nigeria. It brings together perspectives from HR professionals and managers across different industries.
30 Contract Staffing Risks That Could Get Your Company SuedThis piece outlines 30 contract staffing risks that have real legal consequences under Nigerian law. If you are a business owner, HR professional, or staffing agency operator, you will find this highly valuable.
10 Steps to Building an Effective Talent PipelineLearn how to keep a list of good candidates ready in advance, before a role becomes vacant. Discover step by step the process of building a talent pipeline that works.
2026 / 2027 NEPL / OERNL Joint Venture Tertiary Scholarship Scheme (National Merit Award)The NEPL/OERNL Joint Venture in pursuance of its Corporate Social Responsibility invites suitably qualified applicants for its 2026/2027 Tertiary Scholarship Scheme, commencing Tuesday, March 3, 2026, and concluding on Wednesday, April 1, 2026. For applicants from Non-Host/Transit Communities